Myocardial blood flow
Regadenoson causes a rapid increase in Coronary Blood Flow (CBF), which is sustained for a several minutes. In patients undergoing coronary catheterisation, pulsed-wave Doppler ultrasonography was used to measure the average peak velocity (APV) of CBF before and up to 30 minutes after administration of Rapiscan (400 mcg, intravenously). Mean APV increased to greater than twice baseline by 30 seconds and decreased to less than half of the maximal effect within 10 minutes (see figure) 1
Aminophylline (100 mg, administered by slow intravenous injection over 60 seconds) injected 1 minute after 400 mcg regadenoson in subjects undergoing cardiac catheterisation, was shown to shorten the duration of the coronary blood flow response to regadenoson.
- Lieu HD, Shryock JC, von Mering GO, et al. Rapiscan, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007;14:514-520 (View abstract)